Financhill
Buy
60

IRTC Quote, Financials, Valuation and Earnings

Last price:
$135.15
Seasonality move :
3.13%
Day range:
$131.81 - $135.85
52-week range:
$55.92 - $137.49
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.85x
P/B ratio:
49.80x
Volume:
805.9K
Avg. volume:
466.7K
1-year change:
26.54%
Market cap:
$4.3B
Revenue:
$591.8M
EPS (TTM):
-$3.14

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IRTC
iRhythm Technologies
$153.4M -$0.94 17.49% -27.01% $137.33
ATRC
AtriCure
$122.9M -$0.22 11.96% -4.31% $49.89
MASI
Masimo
$367.8M $1.21 -25.37% 192.38% $195.70
OM
Outset Medical
$27.8M -$0.95 -1.24% -74.96% $21.75
PODD
Insulet
$543.3M $0.79 18.28% -65.84% $313.60
RMD
ResMed
$1.3B $2.36 8.17% 24.05% $264.49
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IRTC
iRhythm Technologies
$135.18 $137.33 $4.3B -- $0.00 0% 6.85x
ATRC
AtriCure
$29.85 $49.89 $1.5B -- $0.00 0% 2.93x
MASI
Masimo
$161.47 $195.70 $8.7B 116.80x $0.00 0% 4.17x
OM
Outset Medical
$11.54 $21.75 $204.3M -- $0.00 0% 0.35x
PODD
Insulet
$258.87 $313.60 $18.2B 44.71x $0.00 0% 9.23x
RMD
ResMed
$241.95 $264.49 $35.5B 27.15x $0.53 0.86% 7.11x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IRTC
iRhythm Technologies
88.19% 0.908 19.37% 5.40x
ATRC
AtriCure
11.98% 2.163 3.87% 2.67x
MASI
Masimo
42.11% 1.411 8.64% 1.08x
OM
Outset Medical
88.04% 2.513 335.86% 4.28x
PODD
Insulet
53.47% 1.663 7.6% 2.50x
RMD
ResMed
10.82% 0.505 2.05% 1.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IRTC
iRhythm Technologies
$109.2M -$32.6M -13.41% -112.03% -17.37% -$17.3M
ATRC
AtriCure
$92.6M -$6M -7.31% -8.3% -4.12% -$13.2M
MASI
Masimo
$244.7M -$54.6M -14.23% -23.05% -58.55% $47.5M
OM
Outset Medical
$10.7M -$21.9M -50.08% -178.08% -67.25% -$16.5M
PODD
Insulet
$430.9M $109.3M 17.64% 43.11% 20.08% $91.7M
RMD
ResMed
$766.4M $426.3M 22.47% 25.76% 33% $554.9M

iRhythm Technologies vs. Competitors

  • Which has Higher Returns IRTC or ATRC?

    AtriCure has a net margin of -19.35% compared to iRhythm Technologies's net margin of -5.46%. iRhythm Technologies's return on equity of -112.03% beat AtriCure's return on equity of -8.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    ATRC
    AtriCure
    74.93% -$0.14 $516.5M
  • What do Analysts Say About IRTC or ATRC?

    iRhythm Technologies has a consensus price target of $137.33, signalling upside risk potential of 1.59%. On the other hand AtriCure has an analysts' consensus of $49.89 which suggests that it could grow by 67.13%. Given that AtriCure has higher upside potential than iRhythm Technologies, analysts believe AtriCure is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    ATRC
    AtriCure
    5 0 0
  • Is IRTC or ATRC More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison AtriCure has a beta of 1.571, suggesting its more volatile than the S&P 500 by 57.127%.

  • Which is a Better Dividend Stock IRTC or ATRC?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AtriCure offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. AtriCure pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IRTC or ATRC?

    iRhythm Technologies quarterly revenues are $158.7M, which are larger than AtriCure quarterly revenues of $123.6M. iRhythm Technologies's net income of -$30.7M is lower than AtriCure's net income of -$6.7M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while AtriCure's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 6.85x versus 2.93x for AtriCure. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    6.85x -- $158.7M -$30.7M
    ATRC
    AtriCure
    2.93x -- $123.6M -$6.7M
  • Which has Higher Returns IRTC or MASI?

    Masimo has a net margin of -19.35% compared to iRhythm Technologies's net margin of -58.2%. iRhythm Technologies's return on equity of -112.03% beat Masimo's return on equity of -23.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    MASI
    Masimo
    40.74% -$6.52 $1.8B
  • What do Analysts Say About IRTC or MASI?

    iRhythm Technologies has a consensus price target of $137.33, signalling upside risk potential of 1.59%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 21.2%. Given that Masimo has higher upside potential than iRhythm Technologies, analysts believe Masimo is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    MASI
    Masimo
    4 3 0
  • Is IRTC or MASI More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

  • Which is a Better Dividend Stock IRTC or MASI?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IRTC or MASI?

    iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Masimo quarterly revenues of $600.7M. iRhythm Technologies's net income of -$30.7M is higher than Masimo's net income of -$349.6M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 6.85x versus 4.17x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    6.85x -- $158.7M -$30.7M
    MASI
    Masimo
    4.17x 116.80x $600.7M -$349.6M
  • Which has Higher Returns IRTC or OM?

    Outset Medical has a net margin of -19.35% compared to iRhythm Technologies's net margin of -87.01%. iRhythm Technologies's return on equity of -112.03% beat Outset Medical's return on equity of -178.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    OM
    Outset Medical
    36.47% -$7.35 $224.2M
  • What do Analysts Say About IRTC or OM?

    iRhythm Technologies has a consensus price target of $137.33, signalling upside risk potential of 1.59%. On the other hand Outset Medical has an analysts' consensus of $21.75 which suggests that it could grow by 88.48%. Given that Outset Medical has higher upside potential than iRhythm Technologies, analysts believe Outset Medical is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    OM
    Outset Medical
    3 2 0
  • Is IRTC or OM More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IRTC or OM?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IRTC or OM?

    iRhythm Technologies quarterly revenues are $158.7M, which are larger than Outset Medical quarterly revenues of $29.5M. iRhythm Technologies's net income of -$30.7M is lower than Outset Medical's net income of -$25.6M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 6.85x versus 0.35x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    6.85x -- $158.7M -$30.7M
    OM
    Outset Medical
    0.35x -- $29.5M -$25.6M
  • Which has Higher Returns IRTC or PODD?

    Insulet has a net margin of -19.35% compared to iRhythm Technologies's net margin of 16.85%. iRhythm Technologies's return on equity of -112.03% beat Insulet's return on equity of 43.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    PODD
    Insulet
    72.12% $1.39 $2.6B
  • What do Analysts Say About IRTC or PODD?

    iRhythm Technologies has a consensus price target of $137.33, signalling upside risk potential of 1.59%. On the other hand Insulet has an analysts' consensus of $313.60 which suggests that it could grow by 21.14%. Given that Insulet has higher upside potential than iRhythm Technologies, analysts believe Insulet is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    PODD
    Insulet
    13 5 0
  • Is IRTC or PODD More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

  • Which is a Better Dividend Stock IRTC or PODD?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IRTC or PODD?

    iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Insulet quarterly revenues of $597.5M. iRhythm Technologies's net income of -$30.7M is lower than Insulet's net income of $100.7M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Insulet's PE ratio is 44.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 6.85x versus 9.23x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    6.85x -- $158.7M -$30.7M
    PODD
    Insulet
    9.23x 44.71x $597.5M $100.7M
  • Which has Higher Returns IRTC or RMD?

    ResMed has a net margin of -19.35% compared to iRhythm Technologies's net margin of 28.26%. iRhythm Technologies's return on equity of -112.03% beat ResMed's return on equity of 25.76%.

    Company Gross Margin Earnings Per Share Invested Capital
    IRTC
    iRhythm Technologies
    68.83% -$0.97 $733.9M
    RMD
    ResMed
    59.33% $2.48 $6.2B
  • What do Analysts Say About IRTC or RMD?

    iRhythm Technologies has a consensus price target of $137.33, signalling upside risk potential of 1.59%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 9.32%. Given that ResMed has higher upside potential than iRhythm Technologies, analysts believe ResMed is more attractive than iRhythm Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    IRTC
    iRhythm Technologies
    9 1 0
    RMD
    ResMed
    8 6 1
  • Is IRTC or RMD More Risky?

    iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

  • Which is a Better Dividend Stock IRTC or RMD?

    iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. iRhythm Technologies pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios IRTC or RMD?

    iRhythm Technologies quarterly revenues are $158.7M, which are smaller than ResMed quarterly revenues of $1.3B. iRhythm Technologies's net income of -$30.7M is lower than ResMed's net income of $365M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while ResMed's PE ratio is 27.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 6.85x versus 7.11x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IRTC
    iRhythm Technologies
    6.85x -- $158.7M -$30.7M
    RMD
    ResMed
    7.11x 27.15x $1.3B $365M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Broadcom Stock a Millionaire Maker?
Is Broadcom Stock a Millionaire Maker?

Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…

Is Berkshire The Best Stock to Buy in a Bad Market?
Is Berkshire The Best Stock to Buy in a Bad Market?

Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…

Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?

The big picture trends in e‑commerce sales are clearly in…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
60
RGC alert for May 7

Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.

Buy
77
FARO alert for May 7

Faro Technologies [FARO] is up 34.66% over the past day.

Buy
63
SKX alert for May 7

Skechers USA [SKX] is down 0.07% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock